logo

For the Inventor, By the Inventor

Santa Cruz, CA, United States of America

Phillip Berman

This inventor holds 6 USPTO granted patents and 1 EPO patent. Top assignee: University of California. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Phillip Berman. Retrieved from https://idiyas.com/inventor/phillip-berman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 50.0

 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal6 out of 16,035 
 
University of California
 patents

Years Active: 2017-2026

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents
1. 12559526 - Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins (2026-02-24),
2. 10517942 - Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120 (2019-12-31),
3. 10507239 - V1/V2 fragments of a HIV-1 envelope glycoprotein (2019-12-17),
4. 10201603 - Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity (2019-02-12),
5. 9782472 - Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity (2017-10-10),
6. 9731002 - HIV-1 GP 120 V1/V2 antigens and immunological uses thereof (2017-08-15),

Title: The Innovative Contributions of Phillip Berman

Introduction

Phillip Berman is a notable inventor based in Santa Cruz, CA. He has made significant contributions to the field of biopharmaceuticals and vaccine development. With a total of 6 patents to his name, Berman's work is at the forefront of scientific innovation.

Latest Patents

Among his latest patents are groundbreaking inventions such as "Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins." Additionally, he has developed polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp120. His work on the creation of HIV-1 vaccine immunogens is particularly noteworthy. These immunogens are based on glycopeptide scaffolds containing sequences from the V1/V2/V3 and C3 domains of HIV-1 gp120. They are designed to bind multiple broadly neutralizing antibodies when expressed in mammalian cells that incorporate mannose-5 and mannose-9 glycans.

Career Highlights

Phillip Berman is affiliated with the University of California, where he continues to push the boundaries of research in his field. His innovative approaches have garnered attention and respect within the scientific community.

Collaborations

Berman has collaborated with esteemed colleagues such as Javier Morales and Bin Yu. Their combined expertise enhances the impact of their research and innovations.

Conclusion

Phillip Berman's contributions to vaccine development and biopharmaceuticals exemplify the spirit of innovation in science. His patents and collaborative efforts continue to pave the way for advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…